WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here

Search

Track Your Article

Abstract

CLINICAL STUDY TO EVALUATE THE EFFICIENCY OF VARUNADI GANA KWATH BHAVITAM SHILAJATU RASAYANA AS ADJUVANT THERAPY IN THE MANAGEMENT OF VATASTHEELA W.S.R. TO PROSTATE CANCER

Dr. Ashutosh K. Tripathi*, Dr. Deepak Kulshreshta, Dr. J. K. Jain, Dr. Shalini Tewari and Dr. Swapnil Singhai

ABSTRACT

Prostate cancer shows that more than 95% of malignancies in prostate are adinocarcinomas. The typical adenocarcinoma of the prostate can be distinguished using PSA immunochemistry. A possible precursor of prostatic carcinoma is prostatic intraepithelial neoplasia. It involves the abnormal development of the epithelial cells which line the prostate glands. Prostate tumours are usually slow growing and symptoms may not occur for many years. In the early stages of prostate cancer, there are often no symptoms. However, due to its location surrounding the urethra, symptoms for the disease most commonly affect urination. Prostate cancer symptoms include frequent urination, increased nocturia, difficulty in maintaining a steady stream of urine, hematuria and dysuria. Three standard treatments for localised prostate cancer exist; surgery, radiotherapy and active surveillance. In Ayurveda the Vatastheela have some similarity with Prostate cancer. According to Charaka Samhita, the vitiated Vata obstructed the passage of urinary bladder and anal canal with flatulence causes the formation of mobile, elevated structure, which is associated with severe pain. 100 patients of Vatastheela were diagnosed on the basis of International Prostate symptom score along with PSA were included in this study. Varunadi Gana Kwath Bhavitam Shilajatu Rasayana was administered orally in dose of Madhyama Matra i.e. 24 gm upto 21 days. The overall result showed mild improvement in 94% patients in Group A and marked relief in 46% patients and moderate response in 54% patients in trial group B. There was improvement in quality of life of the patients and PSA level after completion of treatment in group B. No clinically adverse effect reported by the patients nor observed by the researcher during the study. The trial drug causes Srotoshodhana and mainly acts at level of Agni so improve the digestion and create excellence of Saptadhatu. It influences Oja, provides nourishment to the Dhatu and may induce Bala and Vyadhiksamatava or Immunity.

Keywords: Prostate Cancer, Vatastheela, Varunadi Gana Kwath Bhavitam Shilajatu Rasayana.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More